130 related articles for article (PubMed ID: 6651812)
1. Comparative study on the antithrombotic effects of a synthetic thrombin inhibitor and of heparin in animal models.
Hauptmann J; Barth A; Schönberger FP; Markwardt F
Biomed Biochim Acta; 1983; 42(7-8):959-65. PubMed ID: 6651812
[TBL] [Abstract][Full Text] [Related]
2. Anticoagulant and antithrombotic action of the synthetic thrombin inhibitor D-phenylalanyl-L-prolyl-L-arginine nitrile.
Kaiser B; Richter M; Hauptmann J; Markwardt F
Pharmazie; 1991 Feb; 46(2):128-31. PubMed ID: 1852761
[TBL] [Abstract][Full Text] [Related]
3. Antithrombotic activity in vivo of SDZ 217-766, a low-molecular weight thrombin inhibitor in comparison to heparin.
Tapparelli C; Metternich R; Gfeller P; Gafner B; Powling M
Thromb Haemost; 1995 Apr; 73(4):641-7. PubMed ID: 7495072
[TBL] [Abstract][Full Text] [Related]
4. Experimental studies on the antithrombotic and haemorrhagic effects of heparin and a low molecular weight heparin derivative.
Kaiser B; Hauptmann J; Markwardt F
Folia Haematol Int Mag Klin Morphol Blutforsch; 1988; 115(1-2):119-25. PubMed ID: 2459005
[TBL] [Abstract][Full Text] [Related]
5. Antithrombotic and haemorrhagic effects of the naturally occurring thrombin inhibitor hirudin.
Kaiser B; Markwardt F
Folia Haematol Int Mag Klin Morphol Blutforsch; 1988; 115(1-2):41-6. PubMed ID: 2459030
[TBL] [Abstract][Full Text] [Related]
6. Effect of new synthetic heparin mimetics on whole blood thrombin generation in vivo and in vitro in rats.
Hérault JP; Bernat A; Gaich C; Herbert M
Thromb Haemost; 2002 Feb; 87(2):238-44. PubMed ID: 11858483
[TBL] [Abstract][Full Text] [Related]
7. Comparison of thrombin active site and exosite inhibitors and heparin in experimental models of arterial and venous thrombosis and bleeding.
Schumacher WA; Steinbacher TE; Heran CL; Seiler SM; Michel IM; Ogletree ML
J Pharmacol Exp Ther; 1993 Dec; 267(3):1237-42. PubMed ID: 8263785
[TBL] [Abstract][Full Text] [Related]
8. Experimental studies on the antithrombotic action of a highly effective synthetic thrombin inhibitor.
Kaiser B; Markwardt F
Thromb Haemost; 1986 Apr; 55(2):194-6. PubMed ID: 3814237
[TBL] [Abstract][Full Text] [Related]
9. In vivo characterization of a new synthetic thrombin inhibitor.
Knabb RM; Kettner CA; Timmermans PB; Reilly TM
Thromb Haemost; 1992 Jan; 67(1):56-9. PubMed ID: 1615483
[TBL] [Abstract][Full Text] [Related]
10. Experimental thrombosis on a collagen coated arterioarterial shunt in rats: a pharmacological model to study antithrombotic agents inhibiting thrombin formation and platelet deposition.
Freund M; Mantz F; Nicolini P; Gachet C; Mulvihill J; Meyer L; Beretz A; Cazenave JP
Thromb Haemost; 1993 May; 69(5):515-21. PubMed ID: 8322274
[TBL] [Abstract][Full Text] [Related]
11. Antithrombotic effect of Glycyrrhizin, a plant-derived thrombin inhibitor.
Mendes-Silva W; Assafim M; Ruta B; Monteiro RQ; Guimarães JA; Zingali RB
Thromb Res; 2003; 112(1-2):93-8. PubMed ID: 15013279
[TBL] [Abstract][Full Text] [Related]
12. Antithrombotic properties of SSR182289A, a new, orally active thrombin inhibitor.
Lorrain J; Millet L; Lechaire I; Lochot S; Ferrari P; Visconte C; Sainte-Marie M; Lunven C; Berry CN; Schaeffer P; Herbert JM; O'Connor SE
J Pharmacol Exp Ther; 2003 Feb; 304(2):567-74. PubMed ID: 12538808
[TBL] [Abstract][Full Text] [Related]
13. Recombinant full-length tissue factor pathway inhibitor (TFPI) prevents thrombus formation and rethrombosis after lysis in a rabbit model of jugular vein thrombosis.
Kaiser B; Fareed J
Thromb Haemost; 1996 Oct; 76(4):615-20. PubMed ID: 8903005
[TBL] [Abstract][Full Text] [Related]
14. An algal sulfated galactan has an unusual dual effect on venous thrombosis due to activation of factor XII and inhibition of the coagulation proteases.
Melo FR; Mourão PA
Thromb Haemost; 2008 Mar; 99(3):531-8. PubMed ID: 18327401
[TBL] [Abstract][Full Text] [Related]
15. The venous antithrombotic effect of LF 1351 in the rat following oral administration.
Millet J; Theveniaux J; Brown NL
Thromb Haemost; 1992 Jan; 67(1):176-9. PubMed ID: 1615473
[TBL] [Abstract][Full Text] [Related]
16. Antithrombotic effect of two low molecular weight thrombin inhibitors and a low-molecular weight heparin in a caval vein thrombosis model in the rat.
Eriksson BI; Carlsson S; Halvarsson M; Risberg B; Mattsson C
Thromb Haemost; 1997 Nov; 78(5):1404-7. PubMed ID: 9408027
[TBL] [Abstract][Full Text] [Related]
17. Inhibition by D-MePhe-Pro-Arg-H (GYKI-14766) of thrombus growth in experimental models of thrombosis.
Bagdy D; Szabó G; Barabás E; Bajusz S
Thromb Haemost; 1992 Aug; 68(2):125-9. PubMed ID: 1412156
[TBL] [Abstract][Full Text] [Related]
18. Dissociation of antithrombotic effect and bleeding time prolongation in rabbits by inhibiting tissue factor function.
Himber J; Kirchhofer D; Riederer M; Tschopp TB; Steiner B; Roux SP
Thromb Haemost; 1997 Sep; 78(3):1142-9. PubMed ID: 9308768
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological studies on the low molecular weight heparin derivative CY 216.
Kaiser B; Kühnemuth G; Markwardt F
Pharmazie; 1990 Jul; 45(7):522-4. PubMed ID: 2173004
[TBL] [Abstract][Full Text] [Related]
20. SR123781A, a synthetic heparin mimetic.
Herbert JM; Hérault JP; Bernat A; Savi P; Schaeffer P; Driguez PA; Duchaussoy P; Petitou M
Thromb Haemost; 2001 May; 85(5):852-60. PubMed ID: 11372679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
